research Utility of Dermoscopy in Alopecia Areata
Dermoscopy is a useful tool for diagnosing and managing alopecia areata.
Search
for
Sort by
Research
60-90 / 1000+ results
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Consensus on the Treatment of Alopecia Areata – Brazilian Society of Dermatology
Tailored treatments for alopecia areata are recommended based on severity and patient needs.
research Efficacy and Safety of Tofacitinib Therapy in Asian Patients with Severe Alopecia Areata
Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
research CTLA4 +49AG (rs231775) And CT60 (rs3087243) Gene Variants Are Not Associated With Alopecia Areata In A Mexican Population From Monterrey, Mexico
CTLA4 gene variants are not linked to alopecia areata in Monterrey's Mexican population.
research Unveiling the Effect of Age and IgE Level on Alopecia Areata: Insights from Comparative RNAseq Analysis
Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
research Steroid-Free Monotherapy with Tofacitinib in Severe Therapy-Resistant Alopecia: A Retrospective Analysis
Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
research Pathomechanisms of Immune-Mediated Alopecia
The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.
research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Diagnosis And Management Of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Therapeutic Potential of Oral Tofacitinib in Alopecia Areata: A Retrospective Study
Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Alopecia Areata: An Evidence-Based Treatment Update
Some treatments, like corticosteroids and sensitizing agents, can help with alopecia areata, but more high-quality research is needed.
research Combination Tofacitinib and Oral Minoxidil Treatment for Severe Alopecia Areata
Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
research Hair Loss And Its Management In Children
The document concludes that early diagnosis and a comprehensive treatment plan are crucial for managing hair loss in children, with a focus on both medical and psychological support.
research The Evaluation of JAK Inhibitors on Effect and Safety in Alopecia Areata: A Systematic Review and Meta-Analysis of 2018 Patients
JAK inhibitors help hair regrowth in alopecia areata but have a high risk of side effects.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research Epigallocatechin Gallate and Tannic Acid Based Formulations of Finasteride for Dermal Administration and Chemoembolization
Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
research The Medical and Psychosocial Associations of Alopecia: Recognizing Hair Loss as More Than a Cosmetic Concern
Alopecia is linked to various health and mental conditions, impacts life quality, and needs medical attention beyond its cosmetic effects.
research Treatment of Alopecia Areata with Nonablative Fractional Laser Combined with Topical Minoxidil
Using a nonablative fractional laser with topical minoxidil can effectively and safely promote hair regrowth in alopecia areata patients.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.